Date Filed |
Document No. |
Description |
Snippet |
Link To Document |
2012-02-17 |
1 |
|
primary exclusivity stemmed from U.S. Patent No. 4,602,017 (“the ‘017 patent”) which
GSK listed in the FDA …017 patent, and these cases were subsequently consolidated
(the “Patent Litigation”). The Patent Litigation…Lamictal Tablets. The ‘017 patent, along with another patent
(U.S. Patent No. 5,698,226), was listed…infringed patent. No relevant regulatory exclusivities extended the life of the ‘017
patent itself per…the
‘017 patent. Thus, even though Teva had already succeeded in invalidating the ‘017 patent’s
primary |
External link to document |
2014-01-24 |
128 |
|
lamotrigine, covered by U.S. Patent No. 4,602,017 (“the ‘017 patent”). Id. ¶ 11. GSK’s patent for
lamotrigine…a “quick look”: if a patent holder makes a reverse
payment to a generic patent challenger, that payment…validity of the patent;
and parties may well find ways to settle patent disputes without…compensates the patent challenger for “other services . . . such as
distributing the patented item or helping…skeptically at patent settlements than did courts applying the
“scope of the patent” test and there |
External link to document |
2016-09-26 |
188 |
Exhibit A |
241” OR “20-764”)
“4,602,017” OR “017 patent” OR “5,698,226” OR “226 patent”
“2:02-cv-03779” OR…SmithKline*) AND Teva AND (settl* OR licens* OR patent*
OR infring* OR agree* OR (hatch w/2 waxman)…SmithKline*) AND Teva AND (settl* OR licens* OR patent*
OR infring* OR agree* OR (hatch w/2 waxman) |
External link to document |
2017-10-18 |
285 |
|
: # 1 Joint Stipulation Regarding U.S. Patent Number 5,698,226)(PEARLMAN, PETER) (Entered: 10/18/2017) |
External link to document |
2017-10-19 |
289 |
|
JOINT STIPULATION AND ORDER REGARDINGU.S. PATENT NO. 5,698,226. Signed by Magistrate Judge Cathy L. Waldor |
External link to document |
Date Filed |
Document No. |
Description |
Snippet |
Link To Document |
This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial